十年的尿抑素发展用于感染的 PET 成像：系统综述。
A decade of ubiquicidin development for PET imaging of infection: A systematic review.
机构信息
Radiochemistry, The South African Nuclear Energy Corporation, Pelindaba, South Africa.
Nuclear Medicine Research Infrastructure NPC, Pretoria, South Africa.
出版信息
Nucl Med Biol. 2023 Jan-Feb;116-117:108307. doi: 10.1016/j.nucmedbio.2022.11.001. Epub 2022 Nov 13.
BACKGROUND
Ubiquicidin is a peptide fragment with selective binding to negatively charged bacterial cell membranes. Besides its earlier labelling with gamma emitting radionuclides, it has been labelled with Positron Emission Tomography (PET) radionuclides in the last decade for imaging infection and distinguishing infectious disease from sterile inflammation. This systematic review aims to evaluate the technology readiness level of PET based ubiquicidin radiopharmaceuticals.
METHODS
Two independent researchers reviewed all articles and abstracts pertaining ubiquicidin and PET imaging that are currently available. Scopus, Google Scholar and PubMed/Medline were used in the search. Upon completion of the literature search all articles and abstracts were evaluated and duplicates were excluded. All non-PET articles as well as review articles without new data were deemed ineligible.
RESULTS
From a total of 17 papers and 10 abstracts the studies were grouped into development, preclinical and clinical studies. Development was published in 15/17 (88%) publications and 6/10 (60%) abstracts, preclinical applications in 9/17 (53%) publications and 1/10 (10%) of abstracts. Finally, clinical studies made up 6/17 (35%) of full publications and 4/10 (40%) of the available abstracts. Development results were the most abundant. All the findings in the different areas of development of ubiquicidin as PET radiopharmaceutical are summarized in this paper.
CONCLUSION
Labelling procedures are generally uncomplicated and relatively fast and there are indications of adequate product stability. The production of PET radiopharmaceuticals based on UBI will therefore not be a barrier for clinical introduction of this technology. Systematization and unification of criteria for preclinical imaging and larger clinical trials are needed to ensure the translation of this radiopharmaceutical into the clinic. Therefore a conclusion with regards to the clinical relevance of ubiquicidin based PET is not yet possible.
背景
尿抑素是一种具有选择性结合带负电荷细菌细胞膜的肽段。除了早期用放射性核素进行标记外，在过去十年中，它还被用于正电子发射断层扫描（PET）放射性核素来成像感染，并区分感染性疾病和无菌性炎症。本系统评价旨在评估基于 PET 的尿抑素放射性药物的技术准备水平。
方法
两名独立的研究人员审查了目前可获得的与尿抑素和 PET 成像相关的所有文章和摘要。在搜索中使用了 Scopus、Google Scholar 和 PubMed/Medline。完成文献搜索后，评估了所有文章和摘要，并排除了重复项。所有非 PET 文章以及没有新数据的综述文章均被视为不合格。
结果
从总共 17 篇论文和 10 篇摘要中，研究分为开发、临床前和临床研究。开发在 15/17（88%）的出版物和 6/10（60%）的摘要中发表，临床前应用在 9/17（53%）的出版物和 1/10（10%）的摘要中发表。最后，临床研究占 17/17（35%）的全文和 10/10（40%）的摘要。开发结果最为丰富。本文总结了尿抑素作为 PET 放射性药物在不同开发领域的所有发现。
结论
标记程序通常不复杂，相对较快，并且有足够的产品稳定性迹象。因此，基于 UBI 的 PET 放射性药物的生产不会成为该技术临床应用的障碍。需要系统和统一的临床前成像标准和更大的临床试验，以确保这种放射性药物转化为临床应用。因此，基于尿抑素的 PET 的临床相关性尚不能得出结论。
Zotero 插件